Berkeley Biosciences, Inc. Launches New Formulation of ActivaMune Diindolylmethane DIM
Natural Immune Booster Exclusively Licensed from UC Berkeley
Berkeley BioSciences, Inc. has launched a new formulation of natural immune system booster,
ActivaMune based on a breakthrough discovery by the Chairman of the Nutritional Sciences
Department and the NIH Director of Cancer Research at UC Berkeley regarding the compound
Diindolylmethane (DIM) from broccoli which has been discovered to potently activate the
immune system. This natural immune booster enhances the immune system and supports
multiple organs throughout the body. The new formulation consists of: 800 mg ActivaMune
DIM Complex, 800 IU Vitamin D3, 60 mg Vitamin C, 30 IU Vitamin E, 50 mg Calcium, 50 mcg
Selenium, 6mg Lutein, 6mg Lycopene, 500 mcg Zeaxanthin and 300 mcg Sulforaphane.
Talking about the discovery at Berkeley, Clinical Immunologist Dr. Janet Baum stated, “This
discovery at Berkeley is one of the most profound discoveries in the field of immunology. Its
implications are so far reaching that it is worthy of a Nobel Prize nomination. One cannot
review the data without experiencing a eureka moment.”
This Diindolylmethane DIM supplement is a product that works best when taken on a regular
basis as a part of one’s nutritional wellness regimen. A bottle of ActivaMune has 60 vegetarian
capsules. Consumers are advised to take 2 capsules a day. By joining the US and International
Quarterly Program, customers can get three bottles of ActivaMune sent to them every three
months with free shipping worldwide.
ActivaMune is a patented formula exclusively marketed by Berkeley BioSciences, Inc. under
license from the University of California at Berkeley.
About the Company:
Berkeley BioSciences Inc. is dedicated to helping people lead healthier lives through the
development of first-in-class nutrition and healthcare products based on rigorous scientific
research and proprietary knowledge. The company has two divisions: Nutraceutical and
Biopharmaceutical. The Nutraceutical Division markets ActivaMune and the
Biopharmaceutical Division is researching and developing nature-based therapeutics for
multiple forms of cancer (breast, prostate, lung, colon and cervical) and infectious diseases like
AIDS, SARS, Hepatitis, HPV, Influenza, Pandemic Flu.
For more information, please visit http://www.activamune.com